Polyphenols in Health and Disease

Cell Biochemistry and Biophysics

Volumn 73, Issue 3, 2015, Pages 649-664

  Zhang, Pei Ying ^a  

^a XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Cardiac disorders; Pathways; Polyphenols

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; CARDIOTONIC AGENT; ENZYME INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPHENOL;

ANIMAL; HUMAN; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; CARDIOTONIC AGENTS; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; POLYPHENOLS;

EID: 84946476823     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-015-0558-z     Document Type: Article

References (185)

1. Yang, C. S., Maliakal, P., & Meng, X. (2002). Inhibition of carcinogenesis by tea. Annual Review of Pharmacology and Toxicology,42, 25–54.
2. Yang, H., Magilnick, N., Lee, C., Kalmaz, D., Ou, X., Chan, J. Y., & Lu, S. C. (2005). Nrf1 and Nrf2 regulate rat glutamate-cysteine ligase catalytic subunit transcription indirectly via NF-kappaB and AP-1. Molecular and Cellular Biology,25, 5933–5946.
3. Ju, J., Lu, G., Lambert, J. D., & Yang, C. S. (2007). Inhibition of carcinogenesis by tea constituents. Seminars in Cancer Biology,17, 395–402.
4. Ju, J., Hong, J., Zhou, J. N., Pan, Z., Bose, M., Liao, J., et al. (2005). Inhibition of intestinal tumorigenesis in Apcmin/+mice by (−)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Research,65, 10623–10631.
5. Lu, Y. P., Lou, Y. R., Xie, J. G., Peng, Q. Y., Zhou, S., Lin, Y., et al. (2007). Caffeine and caffeine sodium benzoate have a sunscreen effect, enhance UVB-induced apoptosis, and inhibit UVB-induced skin carcinogenesis in SKH-1 mice. Carcinogenesis,28, 199–206.
6. Gupta, S., Hastak, K., Ahmad, N., Lewin, J. S., & Mukhtar, H. (2001). Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proceedings of National Academy of Science USA,98, 10350–10355.
7. Khan, N., Afaq, F., Saleem, M., Ahmad, N., & Mukhtar, H. (2006). Targeting multiple signaling pathways by green tea polyphenol (−)-epigallocatechin-3-gallate. Cancer Research,66, 2500–2505.
8. Conney, A. H., Zhou, S., Lee, M. J., Xie, J. G., Yang, C. S., Lou, Y. R., & Lu, Y. (2007). Stimulatory effect of oral administration of tea, coffee or caffeine on UVB-induced apoptosis in the epidermis of SKH-1 mice. Toxicology and Applied Pharmacology,224, 209–213.
9. Lu, G., Liao, J., Yang, G., Reuhl, K. R., Hao, X., & Yang, C. S. (2006). Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. Cancer Research,66, 11494–11501.
10. Xu, Y., Ho, C. T., Amin, S. G., Han, C., & Chung, F. L. (1992). Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. Cancer Research,52, 3875–3879.
11. Yang, C. S., Lambert, J. D., Hou, Z., Ju, J., Lu, G., & Hao, X. (2006). Molecular targets for the cancer preventive activity of tea polyphenols. Molecular Carcinogenesis,45, 431–435.
12. Senthil Kumaran, V., Arulmathi, K., Srividhya, R., & Kalaiselvi, P. (2008). Repletion of antioxidant status by EGCG and retardation of oxidative damage induced macromolecular anomalies in aged rats. Experimental Gerontology,2008(43), 176–183.
13. Srividhya, R., Jyothilakshmi, V., Arulmathi, K., Senthilkumaran, V., & Kalaiselvi, P. (2008). Attenuation of senescence-induced oxidative exacerbations in aged rat brain by (−)-epigallocatechin-3-gallate. International Journal of Developmental Neuroscience,26, 217–223.
14. Inami, S., Takano, M., Yamamoto, M., Murakami, D., Tajika, K., Yodogawa, K., et al. (2007). Tea catechin consumption reduces circulating oxidized low-density lipoprotein. International Heart Journal,48, 725–732.
15. Hou, D. X., Masuzaki, S., Tanigawa, S., Hashimoto, F., Chen, J., Sogo, T., & Fujii, M. (2010). Oolong tea theasinensins attenuate cyclooxygenase-2 expression in lipopolysaccharide (LPS)-activated mouse macrophages: Structure-activity relationship and molecular mechanisms. Journal of Agriculture and Food Chemistry,58, 12735–12743.
16. Yang, G. Y., Liao, J., Kim, K., Yurkow, E. J., & Yang, C. S. (1998). Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis,19, 611–616.
17. Na, H. K., & Surh, Y. J. (2008). Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food and Chemical Toxicology,2008(46), 1271–1278.
18. Shen, G., Xu, C., Hu, R., Jain, M. R., Nair, S., Lin, W., et al. (2005). Comparison of (−)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (−/−) mice. Pharmaceutical Research,22, 1805–1820.
19. Yang, C. S., Wang, X., Lu, G., & Picinich, S. C. (2009). Cancer prevention by tea: Animal studies, molecular mechanisms and human relevance. Nature Reviews Cancer,9, 429–439.
20. Tachibana, H., Koga, K., Fujimura, Y., & Yamada, K. (2004). A receptor for green tea polyphenol EGCG. Nature Structural & Molecular Biology,11, 380–381.
21. Leone, M., Zhai, D., Sareth, S., Kitada, S., Reed, J. C., & Pellecchia, M. (2003). Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Research,63, 8118–8121.
22. Dong, Z., Ma, W., Huang, C., & Yang, C. S. (1997). Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (−)-epigallocatechin gallate, and theaflavins. Cancer Research,57, 4414–4419.
23. Ermakova, S., Choi, B. Y., Choi, H. S., Kang, B. S., Bode, A. M., & Dong, Z. (2005). The intermediate filament protein vimentin is a new target for epigallocatechin gallate. Journal of Biological Chemistry,280, 16882–16890.
24. Li, M., He, Z., Ermakova, S., Zheng, D., Tang, F., Cho, Y. Y., et al. (2007). Direct inhibition of insulin-like growth factor-I receptor kinase activity by (−)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiology, Biomarkers & Prevention,16, 598–605.
25. He, Z., Tang, F., Ermakova, S., Li, M., Zhao, Q., Cho, Y. Y., et al. (2008). Fyn is a novel target of (−)-epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation. Molecular Carcinogenesis,47, 172–183.
26. Ermakova, S. P., Kang, B. S., Choi, B. Y., Choi, H. S., Schuster, T. F., Ma, W. Y., et al. (2006). (−)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Research,66, 9260–9269.
27. Shim, J. H., Choi, H. S., Pugliese, A., Lee, S. Y., Chae, J. I., Choi, B. Y., et al. (2008). (−)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase. Journal of Biological Chemistry,283, 28370–28379.
28. Kuzuhara, T., Sei, Y., Yamaguchi, K., Suganuma, M., & Fujiki, H. (2006). DNA and RNA as new binding targets of green tea catechins. Journal of Biological Chemistry,281, 17446–17456.
29. Chung, J. Y., Huang, C., Meng, X., Dong, Z., & Yang, C. S. (1999). Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: Structure–activity relationship and mechanisms involved. Cancer Research,59, 4610–4617.
30. Chung, J. Y., Park, J. O., Phyu, H., Dong, Z., & Yang, C. S. (2001). Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (−)-epigallocatechin-3-gallate and theaflavin-3,3′-digallate. The FASEB Journal,15, 2022–2024.
31. Liang, Y. C., Lin-Shiau, S. Y., Chen, C. F., & Lin, J. K. (1999). Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (−)-epigallocatechin-3-gallate. Journal of Cellular Biochemistry,75, 1–12.
32. Garbisa, S., Sartor, L., Biggin, S., Salvato, B., Benelli, R., & Albini, A. (2001). Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer,91, 822–832.
33. Annabi, B., Lachambre, M. P., Bousquet-Gagnon, N., Page, M., Gingras, D., & Beliveau, R. (2002). Green tea polyphenol (−)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. Biochimica et Biophysica Acta,1542, 209–220.
34. Taniguchi, S., Fujiki, H., Kobayashi, H., Go, H., Miyado, K., Sadano, H., & Shimokawa, R. (1992). Effect of (−)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Letters,65, 51–54.
35. Fang, M. Z., Wang, Y., Ai, N., Hou, Z., Sun, Y., Lu, H., et al. (2003). Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Research,63, 7563–7570.
36. Navarro-Peran, E., Cabezas-Herrera, J., Garcia-Canovas, F., Durrant, M. C., Thorneley, R. N., & Rodriguez-Lopez, J. N. (2005). The antifolate activity of tea catechins. Cancer Research,65, 2059–2064.
37. Shin, E. S., Park, J., Shin, J. M., Cho, D., Cho, S. Y., Shin, D. W., et al. (2008). Catechin gallates are NADP+-competitive inhibitors of glucose-6-phosphate dehydrogenase and other enzymes that employ NADP+ as a coenzyme. Bioorganic & Medicinal Chemistry,16, 3580–3586.
38. Ishii, T., Mori, T., Tanaka, T., Mizuno, D., Yamaji, R., Kumazawa, S., et al. (2008). Covalent modification of proteins by green tea polyphenol (−)-epigallocatechin-3-gallate through autoxidation. Free Radical Biology and Medicine,45, 1384–1394.
39. Adachi, S., Nagao, T., Ingolfsson, H. I., Maxfield, F. R., Andersen, O. S., Kopelovich, L., & Weinstein, I. B. (2007). The inhibitory effect of (−)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Research,67, 6493–6501.
40. Masuda, M., Suzui, M., Lim, J. T., Deguchi, A., Soh, J. W., & Weinstein, I. B. (2002). Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. Journal of Experimental Therapeutics and Oncology,2, 350–359.
41. Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003). Met, metastasis, motility and more. Nature Reviews Molecular Cell Biology,4, 915–925.
42. Bigelow, R. L., & Cardelli, J. A. (2006). The green tea catechins, (−)-Epigallocatechin-3-gallate (EGCG) and (−)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene,2006(25), 1922–1930.
43. Sartippour, M. R., Shao, Z. M., Heber, D., Beatty, P., Zhang, L., Liu, C., et al. (2002). Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. Journal of Nutrition,132, 2307–2311.
44. Rodriguez, S. K., Guo, W., Liu, L., Band, M. A., Paulson, E. K., & Meydani, M. (2006). Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. International Journal of Cancer,118, 1635–1644.
45. Liao, J., Yang, G. Y., Park, E. S., Meng, X., Sun, Y., Jia, D., et al. (2004). Inhibition of lung carcinogenesis and effects on angiogenesis and apoptosis in A/J mice by oral administration of green tea. Nutrition and Cancer,48, 44–53.
46. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., et al. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science,275, 218–220.
47. Athar, M., Back, J. H., Tang, X., Kim, K. H., Kopelovich, L., Bickers, D. R., & Kim, A. L. (2007). Resveratrol: A review of preclinical studies for human cancer prevention. Toxicology and Applied Pharmacology,224, 274–283.
48. Baur, J. A., & Sinclair, D. A. (2006). Therapeutic potential of resveratrol: The in vivo evidence. Nature Reviews Drug Discovery,2006(5), 493–506.
49. Fauconneau, B., Waffo-Teguo, P., Huguet, F., Barrier, L., Decendit, A., & Merillon, J. M. (1997). Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sciences,61, 2103–2110.
50. Jang, D. S., Kang, B. S., Ryu, S. Y., Chang, I. M., Min, K. R., & Kim, Y. (1999). Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochemical Pharmacology,57, 705–712.
51. Pace-Asciak, C. R., Rounova, O., Hahn, S. E., & Goldberg, D. M. (1996). Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clinica Chimica Acta,246, 163–182.
52. Kundu, J. K., & Surh, Y. J. (2004). Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutation Research,2004(555), 65–80.
53. Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., & Takada, Y. (2004). Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Research,24, 2783–2840.
54. Hussain, S. P., & Harris, C. C. (2007). Inflammation and cancer: An ancient link with novel potentials. International Journal of Cancer,2007(121), 2373–2380.
55. Gusman, J., Malonne, H., & Atassi, G. (2001). A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis,22, 1111–1117.
56. Chen, C. Y., Jang, J. H., & Surh, Y. J. (2005). Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochemical and Biophysical Research Communication,331, 993–1000.
57. Hebbar, V., Shen, G., Hu, R., Kim, B. R., Chen, C., Korytko, P. J., et al. (2005). Toxicogenomics of resveratrol in rat liver. Life Sciences,76, 2299–2314.
58. Juan, S. H., Cheng, T. H., Lin, H. C., Chu, Y. L., & Lee, W. S. (2005). Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells. Biochemical Pharmacology,69, 41–48.
59. Kluth, D., Banning, A., Paur, I., Blomhoff, R., & Brigelius-Flohe, R. (2007). Modulation of pregnane X receptor- and electrophile responsive element-mediated gene expression by dietary polyphenolic compounds. Free Radical Biology and Medicine,42, 315–325.
60. Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature,2002(420), 860–867.
61. Bakhle, Y. S. (2001). COX-2 and cancer: A new approach to an old problem. British Journal of Pharmacology,2001(134), 1137–1150.
62. de la Lastra, C. A., & Villegas, I. (2005). Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications. Molecular Nutrition & Food Research,2005(49), 405–430.
63. Subbaramaiah, K., Chung, W. J., Michaluart, P., Telang, N., Tanabe, T., Inoue, H., et al. (1998). Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. Journal of Biological Chemistry,273, 21875–21882.
64. Kundu, J. K., Shin, Y. K., Kim, S. H., & Surh, Y. J. (2006). Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis,27, 1465–1474.
65. Zykova, T. A., Zhu, F., Zhai, X., Ma, W. Y., Ermakova, S. P., Lee, K. W., et al. (2008). Resveratrol directly targets COX-2 to inhibit carcinogenesis. Molecular Carcinogenesis,47, 797–805.
66. Richard, N., Porath, D., Radspieler, A., & Schwager, J. (2005). Effects of resveratrol, piceatannol, tri-acetoxystilbene, and genistein on the inflammatory response of human peripheral blood leukocytes. Molecular Nutrition & Food Research,49, 431–442.
67. Estrov, Z., Shishodia, S., Faderl, S., Harris, D., Van, Q., Kantarjian, H. M., et al. (2003). Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood,102, 987–995.
68. Shen, F., Chen, S. J., Dong, X. J., Zhong, H., Li, Y. T., & Cheng, G. F. (2003). Suppression of IL-8 gene transcription by resveratrol in phorbol ester treated human monocytic cells. Journal of Asian Natural Products Research,5, 151–157.
69. Alao, J. P. (2007). The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Molecular Cancer,2007(6), 24.
70. Murray, A. W. (2004). Recycling the cell cycle: Cyclins revisited. Cell,2004(116), 221–234.
71. Kim, A. L., Zhu, Y., Zhu, H., Han, L., Kopelovich, L., Bickers, D. R., & Athar, D. M. (2006). Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1 signalling pathways. Experimental Dermatology,15, 538–546.
72. Adhami, V. M., Afaq, F., & Ahmad, N. (2001). Involvement of the retinoblastoma (pRb)-E2F/DP pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochemical and Biophysical Research Communication,288, 579–585.
73. Ahmad, N., Adhami, V. M., Afaq, F., Feyes, D. K., & Mukhtar, H. (2001). Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clinical Cancer Research,7, 1466–1473.
74. Joe, A. K., Liu, H., Suzui, M., Vural, M. E., Xiao, D., & Weinstein, I. B. (2002). Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clinical Cancer Research,8, 893–903.
75. Pozo-Guisado, E., Alvarez-Barrientos, A., Mulero-Navarro, S., Santiago-Josefat, B., & Fernandez-Salguero, P. M. (2002). The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: Cell-specific alteration of the cell cycle. Biochemical Pharmacology,64, 1375–1386.
76. Liang, Y. C., Tsai, S. H., Chen, L., Lin-Shiau, S. Y., & Lin, J. K. (2003). Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochemical Pharmacology,65, 1053–1060.
77. Kim, Y. A., Rhee, S. H., Park, K. Y., & Choi, Y. H. (2003). Antiproliferative effect of resveratrol in human prostate carcinoma cells. Journal of Medicinal Food,6, 273–280.
78. Kim, Y. A., Choi, B. T., Lee, Y. T., Park, D. I., Rhee, S. H., Park, K. Y., & Choi, Y. H. (2004). Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncology Reports,11, 441–446.
79. Shimizu, T., Nakazato, T., Xian, M. J., Sagawa, M., Ikeda, Y., & Kizaki, M. (2006). Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways. Biochemical Pharmacology,71, 742–750.
80. Tyagi, A., Singh, R. P., Agarwal, C., Siriwardana, S., Sclafani, R. A., & Agarwal, R. (2005). Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis,26, 1978–1987.
81. Garvin, S., Ollinger, K., & Dabrosin, C. (2006). Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Letters,231, 113–122.
82. Kalra, N., Roy, P., Prasad, S., & Shukla, Y. (2008). Resveratrol induces apoptosis involving mitochondrial pathways in mouse skin tumorigenesis. Life Sciences,82, 348–358.
83. van Ginkel, P. R., Sareen, D., Subramanian, L., Walker, Q., Darjatmoko, S. R., Lindstrom, M. J., et al. (2007). Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clinical Cancer Research,13, 5162–5169.
84. Alkhalaf, M. (2007). Resveratrol-induced apoptosis is associated with activation of p53 and inhibition of protein translation in T47D human breast cancer cells. Pharmacology,80, 134–143.
85. Shankar, S., Singh, G., & Srivastava, R. K. (2007). Chemoprevention by resveratrol: Molecular mechanisms and therapeutic potential. Frontiers in Bioscience,12, 4839–4854.
86. Cecchinato, V., Chiaramonte, R., Nizzardo, M., Cristofaro, B., Basile, A., Sherbet, G. V., & Comi, P. (2007). Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochemical Pharmacology,74, 1568–1574.
87. Su, J. L., Yang, C. Y., Zhao, M., Kuo, M. L., & Yen, M. L. (2007). Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. Journal of Biological Chemistry,282, 19385–19398.
88. Sun, C., Hu, Y., Liu, X., Wu, T., Wang, Y., He, W., & Wei, W. (2006). Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genetics and Cytogenetics,165, 9–19.
89. Clement, M. V., Hirpara, J. L., Chawdhury, S. H., & Pervaiz, S. (1998). Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood,92, 996–1002.
90. Fas, S. C., Baumann, S., Zhu, J. Y., Giaisi, M., Treiber, M. K., Mahlknecht, U., et al. (2006). Wogonin sensitizes resistant malignant cells to TNFalpha- and TRAIL-induced apoptosis. Blood,108, 3700–3706.
91. Sandu, C., Gavathiotis, E., Huang, T., Wegorzewska, I., & Werner, M. H. (2005). A mechanism for death receptor discrimination by death adaptors. Journal of Biological Chemistry,280, 31974–31980.
92. Luschen, S., Falk, M., Scherer, G., Ussat, S., Paulsen, M., & Adam-Klages, S. (2005). The Fas-associated death domain protein/caspase-8/c-FLIP signaling pathway is involved in TNF-induced activation of ERK. Experimental Cell Research,310, 33–42.
93. Wajant, H. (2003). Death receptors. Essays in Biochemistry,39, 53–71.
94. Delmas, D., Rebe, C., Lacour, S., Filomenko, R., Athias, A., Gambert, P., et al. (2003). Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. Journal of Biological Chemistry,278, 41482–41490.
95. Fulda, S., & Debatin, K. M. (2005). Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. European Journal of Cancer,41, 786–798.
96. Bhardwaj, A., Sethi, G., Vadhan-Raj, S., Bueso-Ramos, C., Takada, Y., Gaur, U., et al. (2007). Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood,109, 2293–2302.
97. Dachs, G. U., Patterson, A. V., Firth, J. D., Ratcliffe, P. J., Townsend, K. M., Stratford, I. J., & Harris, A. L. (1997). Targeting gene expression to hypoxic tumor cells. Nature Medicine,3, 515–520.
98. Fruehauf, J. P., & Meyskens, F. L., Jr. (2007). Reactive oxygen species: A breath of life or death? Clinical Cancer Research,13, 789–794.
99. Brown, L. M., Cowen, R. L., Debray, C., Eustace, A., Erler, J. T., Sheppard, F. C., et al. (2006). Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Molecular Pharmacology,69, 411–418.
100. Beppu, K., Nakamura, K., Linehan, W. M., Rapisarda, A., & Thiele, C. J. (2005). Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Research,65, 4775–4781.
101. Mazure, N. M., Chen, E. Y., Laderoute, K. R., & Giaccia, A. J. (1997). Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood,90, 3322–3331.
102. Darland, D. C., & D’Amore, P. A. (1999). Blood vessel maturation: Vascular development comes of age. The Journal of Clinical Investigation,1999(103), 157–158.
103. Neufeld, G., Cohen, T., Gengrinovitch, S., & Poltorak, Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. The FASEB Journal,13, 9–22.
104. Park, C. H., Hahm, E. R., Park, S., Kim, H. K., & Yang, C. H. (2005). The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Letters,579, 2965–2971.
105. Lin, M. T., Yen, M. L., Lin, C. Y., & Kuo, M. L. (2003). Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Molecular Pharmacology,64, 1029–1036.
106. Tang, F. Y., Chiang, E. P., & Sun, Y. C. (2008). Resveratrol inhibits heregulin-beta1-mediated matrix metalloproteinase-9 expression and cell invasion in human breast cancer cells. Journal of Nutritional Biochemistry,19, 287–294.
107. Yu, H., Kortylewski, M., & Pardoll, D. (2007). Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nature Reviews Immunology,7, 41–51.
108. Banerjee, S., Bueso-Ramos, C., & Aggarwal, B. B. (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Research,62, 4945–4954.
109. Li, L., Fink, G. D., Watts, S. W., Northcott, C. A., Galligan, J. J., Pagano, P. J., & Chen, A. F. (2003). Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation,107, 1053–1058.
110. Lee, S. J., & Kim, M. M. (2011). Resveratrol with antioxidant activity inhibits matrix metalloproteinase via modulation of SIRT1 in human fibrosarcoma cells. Life Sciences,2011(88), 465–472.
111. Yu, R., Hebbar, V., Kim, D. W., Mandlekar, S., Pezzuto, J. M., & Kong, A. N. (2001). Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Molecular Pharmacology,60, 217–224.
112. Kundu, J. K., Shin, Y. K., & Surh, Y. J. (2006). Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets. Biochemical Pharmacology,72, 1506–1515.
113. Kotha, A., Sekharam, M., Cilenti, L., Siddiquee, K., Khaled, A., Zervos, A. S., et al. (2006). Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Molecular Cancer Therapeutics,5, 621–629.
114. Hsieh, T. C., Lu, X., Wang, Z., & Wu, J. M. (2006). Induction of quinone reductase NQO1 by resveratrol in human K562 cells involves the antioxidant response element ARE and is accompanied by nuclear translocation of transcription factor Nrf2. Medicinal Chemistry,2, 275–285.
115. Kode, A., Rajendrasozhan, S., Caito, S., Yang, S. R., Megson, I. L., & Rahman, I. (2008). Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. American Journal of Physiology. Lung Cellular and Molecular Physiology,294, L478–L488.
116. Ulrich, S., Loitsch, S. M., Rau, O., von Knethen, A., Brune, B., Schubert-Zsilavecz, M., & Stein, J. M. (2006). Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Research,66, 7348–7354.
117. Baek, S. J., Wilson, L. C., & Eling, T. E. (2002). Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis,23, 425–434.
118. Aggarwal, B. B. (2008). Prostate cancer and curcumin: Add spice to your life. Cancer Biology & Therapy,2008(7), 1436–1440.
119. Elattar, T. M., & Virji, A. S. (2000). The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in vitro. Anticancer Research,2000(20), 1733–1738.
120. Hanif, R., Qiao, L., Shiff, S. J., & Rigas, B. (1997). Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. Journal of Laboratory and Clinical Medicine,130, 576–584.
121. Lin, Y. G., Kunnumakkara, A. B., Nair, A., Merritt, W. M., Han, L. Y., Armaiz-Pena, G. N., et al. (2007). Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clinical Cancer Research,13, 3423–3430.
122. LoTempio, M. M., Veena, M. S., Steele, H. L., Ramamurthy, B., Ramalingam, T. S., Cohen, A. N., et al. (2005). Curcumin suppresses growth of head and neck squamous cell carcinoma. Clinical Cancer Research,11, 6994–7002.
123. Mehta, K., Pantazis, P., McQueen, T., & Aggarwal, B. B. (1997). Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anti-Cancer Drugs,8, 470–481.
124. Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P., & Aggarwal, B. B. (2001). Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene,20, 7597–7609.
125. Siwak, D. R., Shishodia, S., Aggarwal, B. B., & Kurzrock, R. (2005). Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer,104, 879–890.
126. Sreejayan, N., & Rao, M. N. (1996). Free radical scavenging activity of curcuminoids. Arzneimittel-Forschung,46, 169–171.
127. Collett, G. P., Robson, C. N., Mathers, J. C., & Campbell, F. C. (2001). Curcumin modifies Apc(min) apoptosis resistance and inhibits 2-amino 1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) induced tumour formation in Apc(min) mice. Carcinogenesis,22, 821–825.
128. Inano, H., Onoda, M., Inafuku, N., Kubota, M., Kamada, Y., Osawa, T., et al. (1999). Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays. Carcinogenesis,20, 1011–1018.
129. Krishnaswamy, K., Goud, V. K., Sesikeran, B., Mukundan, M. A., & Krishna, T. P. (1998). Retardation of experimental tumorigenesis and reduction in DNA adducts by turmeric and curcumin. Nutrition and Cancer,30, 163–166.
130. Barclay, L. R., Vinqvist, M. R., Mukai, K., Goto, H., Hashimoto, Y., Tokunaga, A., & Uno, H. (2000). On the antioxidant mechanism of curcumin: Classical methods are needed to determine antioxidant mechanism and activity. Organic Letters,2, 2841–2843.
131. Chattopadhyay, J., Biswas, K., Bandyopadhyay, U., & Banerjee, R. K. (2004). Turmeric and curcumin: Biological actions and medicinal applications. Current Science,87, 44–53.
132. Ligeret, H., Barthelemy, S., Zini, R., Tillement, J. P., Labidalle, S., & Morin, D. (2004). Effects of curcumin and curcumin derivatives on mitochondrial permeability transition pore. Free Radical Biology and Medicine,36, 919–929.
133. Vajragupta, O., Boonchoong, P., Watanabe, H., Tohda, M., Kummasud, N., & Sumanont, Y. (2003). Manganese complexes of curcumin and its derivatives: Evaluation for the radical scavenging ability and neuroprotective activity. Free Radical Biology and Medicine,35, 1632–1644.
134. Thapliyal, R., & Maru, G. B. (2001). Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food and Chemical Toxicology,39, 541–547.
135. Iqbal, M., Sharma, S. D., Okazaki, Y., Fujisawa, M., & Okada, S. (2003). Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: Possible role in protection against chemical carcinogenesis and toxicity. Pharmacology and Toxicology,92, 33–38.
136. Andreadi, C. K., Howells, L. M., Atherfold, P. A., & Manson, M. M. (2006). Involvement of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Molecular Pharmacology,69, 1033–1040.
137. Balogun, E., Hoque, M., Gong, P., Killeen, E., Green, C. J., Foresti, R., et al. (2003). Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochemical Journal,371, 887–895.
138. Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., et al. (1997). An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochemical and Biophysical Research Communication,236, 313–322.
139. Pool-Zobel, B., Veeriah, S., & Bohmer, F. D. (2005). Modulation of xenobiotic metabolising enzymes by anticarcinogens—focus on glutathione S-transferases and their role as targets of dietary chemoprevention in colorectal carcinogenesis. Mutation Research,591, 74–92.
140. Leslie, C. C. (1997). Properties and regulation of cytosolic phospholipase A2. Journal of Biological Chemistry,1997(272), 16709–16712.
141. Rao, C. V., Rivenson, A., Simi, B., & Reddy, B. S. (1995). Chemoprevention of colon cancer by dietary curcumin. Annals of the New York Academy of Sciences,768, 201–204.
142. Brennan, P., & O’Neill, L. A. (1998). Inhibition of nuclear factor kappaB by direct modification in whole cells—mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochemical Pharmacology,55, 965–973.
143. Jobin, C., Bradham, C. A., Russo, M. P., Juma, B., Narula, A. S., Brenner, D. A., & Sartor, R. B. (1999). Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. Journal of Immunology,163, 3474–3483.
144. Wang, D., Veena, M. S., Stevenson, K., Tang, C., Ho, B., Suh, J. D., et al. (2008). Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clinical Cancer Research,14, 6228–6236.
145. Han, T. S., Sattar, N., Williams, K., Gonzalez-Villalpando, C., Lean, M. E., & Haffner, S. M. (2002). Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care,25, 2016–2021.
146. Plummer, S. M., Holloway, K. A., Manson, M. M., Munks, R. J., Kaptein, A., Farrow, S., & Howells, L. (1999). Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene,18, 6013–6020.
147. Singh, S., & Aggarwal, B. B. (1995). Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. Journal of Biological Chemistry,270, 24995–25000.
148. Yadav, V. S., Mishra, K. P., Singh, D. P., Mehrotra, S., & Singh, V. K. (2005). Immunomodulatory effects of curcumin. Immunopharmacology and Immunotoxicology,27, 485–497.
149. Grandjean-Laquerriere, A., Gangloff, S. C., Le Naour, R., Trentesaux, C., Hornebeck, W., & Guenounou, M. (2002). Relative contribution of NF-kappaB and AP-1 in the modulation by curcumin and pyrrolidine dithiocarbamate of the UVB-induced cytokine expression by keratinocytes. Cytokine,18, 168–177.
150. Tunstall, R. G., Sharma, R. A., Perkins, S., Sale, S., Singh, R., Farmer, P. B., et al. (2006). Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: Modification by dietary curcumin and implications for clinical trials. European Journal of Cancer,42, 415–421.
151. Began, G., Sudharshan, E., & Appu Rao, A. G. (1998). Inhibition of lipoxygenase 1 by phosphatidylcholine micelles-bound curcumin. Lipids,33, 1223–1228.
152. Skrzypczak-Jankun, E., McCabe, N. P., Selman, S. H., & Jankun, J. (2000). Curcumin inhibits lipoxygenase by binding to its central cavity: Theoretical and X-ray evidence. International Journal of Molecular Medicine,6, 521–526.
153. Notarbartolo, M., Poma, P., Perri, D., Dusonchet, L., Cervello, M., & D’Alessandro, N. (2005). Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Letters,224, 53–65.
154. Atsumi, T., Murakami, Y., Shibuya, K., Tonosaki, K., & Fujisawa, S. (2005). Induction of cytotoxicity and apoptosis and inhibition of cyclooxygenase-2 gene expression, by curcumin and its analog, alpha-diisoeugenol. Anticancer Research,25, 4029–4036.
155. Du, B., Jiang, L., Xia, Q., & Zhong, L. (2006). Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy,52, 23–28.
156. Surh, Y. J., Chun, K. S., Cha, H. H., Han, S. S., Keum, Y. S., Park, K. K., & Lee, S. S. (2001). Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutation Research,480–481, 243–268.
157. Woo, M. S., Jung, S. H., Kim, S. Y., Hyun, J. W., Ko, K. H., Kim, W. K., & Kim, H. S. (2005). Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochemical and Biophysical Research Communication,335, 1017–1025.
158. Aggarwal, B. B., Shishodia, S., Takada, Y., Banerjee, S., Newman, R. A., Bueso-Ramos, C. E., & Price, J. E. (2005). Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clinical Cancer Research,11, 7490–7498.
159. O’Hanlon, D. M., Fitzsimons, H., Lynch, J., Tormey, S., Malone, C., & Given, H. F. (2002). Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. European Journal of Cancer,38, 2252–2257.
160. Lee, C. W., Lin, W. N., Lin, C. C., Luo, S. F., Wang, J. S., Pouyssegur, J., & Yang, C. M. (2006). Transcriptional regulation of VCAM-1 expression by tumor necrosis factor-alpha in human tracheal smooth muscle cells: Involvement of MAPKs, NF-kappaB, p300, and histone acetylation. Journal of Cellular Physiology,207, 174–186.
161. Fujie, H., Moriya, K., Shintani, Y., Tsutsumi, T., Takayama, T., Makuuchi, M., et al. (2001). Frequent beta-catenin aberration in human hepatocellular carcinoma. Hepatology Research,20, 39–51.
162. Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., & Kinzler, K. W. (1997). Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science,275, 1787–1790.
163. Woo, D. K., Kim, H. S., Lee, H. S., Kang, Y. H., Yang, H. K., & Kim, W. H. (2001). Altered expression and mutation of beta-catenin gene in gastric carcinomas and cell lines. International Journal of Cancer,95, 108–113.
164. Morin, P. J. (1999). Beta-catenin signaling and cancer. BioEssays,1999(21), 1021–1030.
165. Rubinfeld, B., Albert, I., Porfiri, E., Fiol, C., Munemitsu, S., & Polakis, P. (1996). Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science,272, 1023–1026.
166. Kildal, W., Risberg, B., Abeler, V. M., Kristensen, G. B., Sudbo, J., Nesland, J. M., & Danielsen, H. E. (2005). Beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: A study in 253 patients. European Journal of Cancer,41, 1127–1134.
167. Yoshida, R., Kimura, N., Harada, Y., & Ohuchi, N. (2001). The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. International Journal of Oncology,18, 513–520.
168. Jaiswal, A. S., Marlow, B. P., Gupta, N., & Narayan, S. (2002). Beta-catenin-mediated transactivation and cell–cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene,21, 8414–8427.
169. Singletary, K., & Milner, J. (2008). Diet, autophagy, and cancer: A review. Cancer Epidemiology Biomarkers & Prevention,17, 1596–1610.
170. Kang, C., & Avery, L. (2008). To be or not to be, the level of autophagy is the question: Dual roles of autophagy in the survival response to starvation. Autophagy,4, 82–84.
171. Bellodi, C., Lidonnici, M. R., Hamilton, A., Helgason, G. V., Soliera, A. R., Ronchetti, M., et al. (2009). Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. The Journal of Clinical Investigation,119, 1109–1123.
172. Harhaji-Trajkovic, L., Vilimanovich, U., Kravic-Stevovic, T., Bumbasirevic, V., & Trajkovic, V. (2009). AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. Journal of Cellular and Molecular Medicine,13, 3644–3654.
173. Li, J., Qin, Z., & Liang, Z. (2009). The prosurvival role of autophagy in Resveratrol-induced cytotoxicity in human U251 glioma cells. BMC Cancer,9, 215.
174. Namgoong, G. M., Khanal, P., Cho, H. G., Lim, S. C., Oh, Y. K., Kang, B. S., et al. (2010). The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. Journal of Biological Chemistry,285, 23829–23841.
175. Ren, J. H., He, W. S., Nong, L., Zhu, Q. Y., Hu, K., Zhang, R. G., et al. (2010). Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biotherapy and Radiopharmaceuticals,25, 75–80.
176. Samaddar, J. S., Gaddy, V. T., Duplantier, J., Thandavan, S. P., Shah, M., Smith, M. J., et al. (2008). A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Molecular Cancer Therapeutics,7, 2977–2987.
177. Song, J., Qu, Z., Guo, X., Zhao, Q., Zhao, X., Gao, L., et al. (2009). Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy,5, 1131–1144.
178. Chiu, H. W., Lin, J. H., Chen, Y. A., Ho, S. Y., & Wang, Y. J. (2010). Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis. Autophagy,6, 353–365.
179. Kanzawa, T., Kondo, Y., Ito, H., Kondo, S., & Germano, I. (2003). Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Research,63, 2103–2108.
180. Qian, W., Liu, J., Jin, J., Ni, W., & Xu, W. (2007). Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leukemia Research,31, 329–339.
181. Basciani, S., Vona, R., Matarrese, P., Ascione, B., Mariani, S., Cauda, R., et al. (2007). Imatinib interferes with survival of multi drug resistant Kaposi’s sarcoma cells. FEBS Letters,581, 5897–5903.
182. Ertmer, A., Huber, V., Gilch, S., Yoshimori, T., Erfle, V., Duyster, J., et al. (2007). The anticancer drug imatinib induces cellular autophagy. Leukemia,21, 936–942.
183. Aoki, H., Takada, Y., Kondo, S., Sawaya, R., Aggarwal, B. B., & Kondo, Y. (2007). Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: Role of Akt and extracellular signal-regulated kinase signaling pathways. Molecular Pharmacology,72, 29–39.
184. Jia, Y. L., Li, J., Qin, Z. H., & Liang, Z. Q. (2009). Autophagic and apoptotic mechanisms of curcumin-induced death in K562 cells. Journal of Asian Natural Products Research,11, 918–928.
185. Shinojima, N., Yokoyama, T., Kondo, Y., & Kondo, S. (2007). Roles of the Akt/mTOR/p70S6 K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy,3, 635–637.